Drug and Gene Delivery Devices Market Size, Share and Growth Outlook, 2026

Drug and Gene Delivery Devices Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Drug and Gene Delivery Devices Market size is forecast to increase from $918.14 Million in 2026 to $1816.07 Million in 2034 at a CAGR of 8.9% between 2026 and 2034.

The Drug and Gene Delivery Devices market report provides detailed analysis and outlook of Drug and Gene Delivery Devices segments including By Vector Type (Viral Vectors, Non-viral Vectors), By Method (In Situ Delivery, Ex Vivo Delivery), By Product Type (Infusion Pumps, Intravenous Catheters, Pre-filled Syringes, Extension Tubes, Sub-retinal Injection Cannulas), By Route of Administration (Oral, Injectable, Inhalation, Transdermal, Ocular, Nasal), By End-User (Pharmaceutical & Biotechnology Companies, Hospitals and Clinics, Contract Research Organizations, Academic and Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Drug and Gene Delivery Devices Industry Overview

Advanced Delivery Platforms Driving Next-Generation Therapeutics

The drug and gene delivery devices industry is evolving rapidly as pharmaceutical companies, biotechnology firms, and medical device manufacturers invest in innovative technologies capable of delivering biologics, gene therapies, and precision medicines more effectively. Growing demand for targeted treatments, self-administration solutions, combination products, and advanced therapeutic modalities is accelerating the development of sophisticated delivery platforms. The industry is increasingly focused on improving treatment accuracy, patient convenience, regulatory compliance, and administration efficiency for biologics, cell and gene therapies, and chronic disease treatments.

Strategic Acquisitions Expanding Drug and Gene Delivery Capabilities

Corporate acquisitions are playing an important role in strengthening delivery technology portfolios. Eli Lilly completed the acquisition of Verve Therapeutics in a transaction valued at up to $1.3 billion. The acquisition enables Lilly to integrate Verve’s in vivo gene-editing programs and associated delivery technologies into its advanced therapeutics pipeline. The strategic focus centers on developing one-time gene-editing treatments and specialized delivery systems targeting chronic cardiovascular diseases, highlighting the growing importance of precision delivery technologies in next-generation medicine.
Embecta Corp. also strengthened its position in the sector through a definitive agreement to acquire Owen Mumford Holdings Limited. The transaction includes an upfront payment of £100 million with additional performance-based consideration of up to £50 million. Through the acquisition, Embecta gains access to Owen Mumford’s Aidaptus next-generation auto-injector platform, expanding its ability to support flexible drug-device and gene-delivery combination products across multiple therapeutic categories worldwide.

Wearable and Large-Volume Delivery Technologies Expanding Treatment Options

Industry collaboration is accelerating innovation in self-administration systems for complex therapies. Datwyler, LTS Device Technologies, and Stevanato Group announced a strategic collaboration aimed at expanding subcutaneous self-delivery solutions for large-volume biologics and novel therapeutic products. Introduced at the Pharmapack exposition in Paris, the integrated platform combines Datwyler’s NeoFlex plungers for controlled drug release, Stevanato Group’s EZ-fill ready-to-use cartridges with capacities up to 20 mL, and LTS wearable smart patch technologies. The solution addresses the mechanical and formulation challenges associated with administering sensitive large-molecule therapies outside traditional healthcare settings, supporting the growing shift toward home-based treatment models.

Regulatory and Validation Support Strengthening Combination Product Development

As drug-device combination products become increasingly complex, regulatory expertise and validation support are becoming critical to successful commercialization. BD announced a strategic partnership with Suttons Creek to assist pharmaceutical and biotechnology developers in navigating regulatory requirements associated with combination delivery systems. The collaboration combines BD’s extensive drug delivery device capabilities with Suttons Creek’s consulting expertise to support design verification, device selection, testing, and validation processes. The initiative is particularly focused on reducing development risks for biologics, small-molecule therapies, and advanced gene-targeted delivery mechanisms, reinforcing the industry's emphasis on robust product development pathways.

Drug and Gene Delivery Devices Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Drug and Gene Delivery Devices market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Gerresheimer AG, West Pharmaceutical Services, Inc., Medtronic plc, Catalent, Inc., Sartorius AG, Danaher Corporation, Pfizer Inc., Merck KGaA. The Drug and Gene Delivery Devices market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Drug and Gene Delivery Devices industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Drug and Gene Delivery Devices Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Drug and Gene Delivery Devices companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Drug and Gene Delivery Devices markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Drug and Gene Delivery Devices Market Competitive Benchmarking and Company Analysis

Leading companies in Drug and Gene Delivery Devices industry include- Thermo Fisher Scientific Inc., Becton, Dickinson and Company (BD), Gerresheimer AG, West Pharmaceutical Services, Inc., Medtronic plc, Catalent, Inc., Sartorius AG, Danaher Corporation, Pfizer Inc., Merck KGaA. The Drug and Gene Delivery Devices market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Drug and Gene Delivery Devices Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Drug and Gene Delivery Devices market remains one of the strongest-performing segments in the country.
The US Drug and Gene Delivery Devices Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Drug and Gene Delivery Devices market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Drug and Gene Delivery Devices industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Drug and Gene Delivery Devices markets

Canada's strong Drug and Gene Delivery Devices sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Drug and Gene Delivery Devices market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Drug and Gene Delivery Devices Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Drug and Gene Delivery Devices market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Drug and Gene Delivery Devices population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Drug and Gene Delivery Devices industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Drug and Gene Delivery Devices market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Drug and Gene Delivery Devices sales through 2034

France Drug and Gene Delivery Devices companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Drug and Gene Delivery Devices Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Drug and Gene Delivery Devices distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Drug and Gene Delivery Devices Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Drug and Gene Delivery Devices market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Drug and Gene Delivery Devices industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Drug and Gene Delivery Devices industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Drug and Gene Delivery Devices Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Drug and Gene Delivery Devices market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Drug and Gene Delivery Devices market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Drug and Gene Delivery Devices Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Drug and Gene Delivery Devices Market Segmentation

By Vector Type
Viral Vectors
Non-viral Vectors
By Method
In Situ Delivery
Ex Vivo Delivery
By Product Type
Infusion Pumps
Intravenous Catheters
Pre-filled Syringes
Extension Tubes
Sub-retinal Injection Cannulas
By Route of Administration
Oral
Injectable
Inhalation
Transdermal
Ocular
Nasal
By End-User
Pharmaceutical & Biotechnology Companies
Hospitals and Clinics
Contract Research Organizations
Academic and Research Institutes

Top Companies in Drug and Gene Delivery Devices Industry

Thermo Fisher Scientific Inc.
Becton, Dickinson and Company (BD)
Gerresheimer AG
West Pharmaceutical Services, Inc.
Medtronic plc
Catalent, Inc.
Sartorius AG
Danaher Corporation
Pfizer Inc.
Merck KGaA

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025